AusperBio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AusperBio - overview
Established
2019
Location
Hangzhou, Zhejiang, China
Primary Industry
Biotechnology
About
Based in Zhejiang, China, and founded in 2019, AusperBio Therapeutics Inc. , or Ausper Biopharma Co. , Ltd. , trading as AusperBio, focuses on intrahepatic and extrahepatic targeted therapy.
The company has acquired Med-Oligo ASO independent intellectual property rights. In August 2026, AusperBio raised USD 120 million in Series C funding led by an investor, with participation from RA Capital Management, Sherpa Healthcare Partners, Hankang Capital, Suzhou Xincheng Private Equity Fund Management, Qiming Venture Partners, YuanBio Venture, CDH Investments, and other investors. The company develops the Med Oligo™ small nucleic acid drug platform, hepatitis B therapeutic vaccine platform, and nasal spray antibody platform. Its R&D drug includes AHB-137, which is a naked antisense oligonucleotide (ASO).
And AHB-137 can treat and prevent chronic hepatitis B and other infectious diseases. The company generates revenue by developing and commercializing oligonucleotide-based therapeutics, advancing its proprietary clinical-stage drug pipeline, and generating revenue through strategic partnerships, licensing agreements, research collaborations, and the future commercialization of treatments targeting hepatitis B, infectious diseases, cancer immunotherapy, and muscle disorders. The Series C funding raised in August 2026 will primarily be used to support the Phase III registration clinical trial and commercialization preparation for AHB-137, accelerate the development of AHB-171 and next-generation combination therapies, and further expand the company's innovative oligonucleotide product pipeline.
Current Investors
Suzhou Xincheng Private Equity Fund Management, Qiming Venture Partners, YuanBio Venture
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.ausperbio.com
Verticals
HealthTech
Company Stage
Series C
Total Amount Raised
Subscriber access only
AusperBio - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C | Completed | AusperBio | - | ||||||||
| Series B | Completed | AusperBio | - | ||||||||
| Series B | Completed | AusperBio | - | ||||||||
| Series B | Completed | AusperBio | - | ||||||||
| Series A | Completed | AusperBio | - |
Displaying 1 - 5 of 7
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.